Evidence map›Paper›PMID 27399284›Full record

ArticleCancer science2016

HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.

Wenwen Wu, Yukiko Togashi, Yoshikazu Johmura, Yasuo Miyoshi, Sachihiko Nobuoka, Makoto Nakanishi, Tomohiko Ohta

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The repair geneOncology reviews · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Wenwen WuDepartment of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
Yukiko TogashiDepartment of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
Yoshikazu JohmuraDepartment of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Yasuo MiyoshiDivision of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.
Sachihiko NobuokaLaboratory Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
Makoto NakanishiDepartment of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Tomohiko OhtaDepartment of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan. to@marianna-u.ac.jp.
St. Marianna University School of Medicine · JPHyogo Medical University · JPNagoya City University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The breast and ovarian cancer predisposition protein BRCA1 forms three mutually exclusive complexes with Fanconi anemia group J protein (FANCJ, also called BACH1 or BRIP1), CtIP, and Abraxas/RAP80 through its BRCA1 C terminus (BRCT) domains, while its RING domain binds to BRCA1-associated RING domain 1 (BARD1). We recently found that the interaction between heterochromatin protein 1 (HP1) and BARD1 is required for the accumulation of BRCA1 and CtIP at sites of DNA double-strand breaks. Here, we investigated the importance of HP1 and BARD1-HP1 interaction in the localization of FANCJ together with the other BRCA1-BRCT binding proteins to clarify the separate role of the HP1-mediated pathway from the RNF8/RNF168-induced ubiquitin-mediated pathway for BRCA1 function. FANCJ interacts with HP1γ in a BARD1-dependent manner, and this interaction was enhanced by ionizing radiation or irinotecan hydrochloride treatment. Simultaneous depletion of all three HP1 isoforms with shRNAs disrupts the accumulation of FANCJ and CtIP, but not RAP80, at double-strand break sites. Replacement of endogenous BARD1 with a mutant BARD1 that is incapable of binding to HP1 also disrupts the accumulation of FANCJ and CtIP, but not RAP80. In contrast, RNF168 depletion disrupts the accumulation of only RAP80, but not FANCJ or CtIP. Consequently, the accumulation of conjugated ubiquitin was only inhibited by RNF168 depletion, whereas the accumulation of RAD51 and sister chromatid exchange were only inhibited by HP1 depletion or disruption of the BARD1-HP1 interaction. Taken together, the results suggest that the BRCA1-FANCJ and BRCA1-CtIP complexes are not downstream of the RNF8/RNF168/ubiquitin pathway, but are instead regulated by the HP1 pathway that precedes homologous recombination DNA repair.

Indexed as

DNA Breaks, Double-StrandedBasic-Leucine Zipper Transcription FactorsCarrier ProteinsCell Line, TumorChromobox Protein Homolog 5Chromosomal Proteins, Non-HistoneDNA-Binding ProteinsDNA DamageDNA RepairEndodeoxyribonucleasesFanconi Anemia Complementation Group ProteinsHeLa CellsHistone ChaperonesHumansModels, BiologicalNuclear ProteinsBACH1 protein, humanBARD1 protein, humanBasic-Leucine Zipper Transcription FactorsCarrier ProteinsChromobox Protein Homolog 5Chromosomal Proteins, Non-HistoneDNA-Binding ProteinsEndodeoxyribonucleasesFanconi Anemia Complementation Group ProteinsHistone ChaperonesNuclear ProteinsRad51 RecombinaseRBBP8 protein, humanRNF168 protein, humanTumor Suppressor ProteinsUbiquitinUbiquitin-Protein LigasesUIMC1 protein, humanBRCA1CtIPDNA damage responseFANCJHP1

Identifiers

PMID27399284
PMCPMC5084677
OpenAlexW2466992456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.